Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / SABS - SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial

SABS - SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial

SAB Biotherapeutics Inc.

  • SAB Biotherapeutics ( NASDAQ: SABS ) is trading 5.6% higher after the company said its fully-human polyclonal antibody platform maintains efficacy against multiple variants of several highly mutating viruses.
  • A Phase 2a challenge trial showed SAB-176 reduced the viral load in subjects exposed to H1N1 influenza virus and improved symptoms by day four and shortened the timeframe for viral shedding.
  • Another study showed that SAB-185 COVID-19 polyclonal antibody therapeutic candidate was effective in animal models against the majority of known SARS-CoV2 variants.

For further details see:

SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial
Stock Information
Company Name: SAB Biotherapeutics Inc.
Stock Symbol: SABS
Market: NASDAQ
Website: sabbiotherapeutics.com
Menu
SABS SABS Quote SABS Short SABS News SABS Articles SABS Message Board
Get SABS Alerts

News, Short Squeeze, Breakout and More Instantly...